Aleta Biotherapeutics

Aleta Biotherapeutics

Biotechnology, 27 Strathmore Rd, Natick, Massachusetts, 01760, United States, 1-10 Employees

aletabio.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 50********

Who is ALETA BIOTHERAPEUTICS

Aletas mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aletas...

Read More

map
  • 27 Strathmore Rd, Natick, Massachusetts, 01760, United States Headquarters: 27 Strathmore Rd, Natick, Massachusetts, 01760, United States
  • 2006 Date Founded: 2006
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 5122

checked-icon Does something look wrong? Fix it. | View contact records from ALETA BIOTHERAPEUTICS

Aleta Biotherapeutics Org Chart and Mapping

Employees

Paul Rennert

Acting CEO, President & CSO

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Aleta Biotherapeutics

Answer: Aleta Biotherapeutics's headquarters are located at 27 Strathmore Rd, Natick, Massachusetts, 01760, United States

Answer: Aleta Biotherapeutics's phone number is 50********

Answer: Aleta Biotherapeutics's official website is https://aletabio.com

Answer: Aleta Biotherapeutics's revenue is Under $1 Million

Answer: Aleta Biotherapeutics's SIC: 5122

Answer: Aleta Biotherapeutics has 1-10 employees

Answer: Aleta Biotherapeutics is in Biotechnology

Answer: Aleta Biotherapeutics contact info: Phone number: 50******** Website: https://aletabio.com

Answer: Aletas mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aletas CAR-T Engager technology incorporates potent multi-antigen targeting, optimal T cell fitness, and persistence to aggressively attack cancers. We use this technology to build programs that solve specific clinical issues, including cell therapy relapses due to antigen loss and the challenge of overcoming solid tumor heterogeneity. Our lead development program has won landmark clinical support from Cancer Research UK and will enter Phase1/2 trials in 2022.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access